Amylin Pharmaceuticals Inc - Current report filing (8-K)
October 17 2007 - 4:20PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 17, 2007
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
0-19700
|
|
33-0266089
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area code:
(858) 552-2200
Check the
appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF
240.13e-4(c))
Item
2.02. Results of Operations and Financial Condition.
On October 17, 2007, Amylin
Pharmaceuticals, Inc. issued a press release announcing its financial
results for the quarter ended September 30, 2007. A copy of this press
release is attached as Exhibit 99.1 and is incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release
issued by Amylin on October 17, 2007
|
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
|
AMYLIN
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
Dated: October
17, 2007
|
By:
|
/s/
Lloyd A. Rowland
|
|
|
|
Lloyd A. Rowland
|
|
|
|
Vice
President, Governance and Compliance,
|
|
|
|
and
Secretary
|
|
3
EXHIBIT
INDEX
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release
issued by Amylin on October 17, 2007.
|
4
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024